AusperBio reports AHB-137 sustained functional cure in 16 of 17 evaluable NA-treated hepatitis B patients at 12 months off ...

Brii Bio's Phase IIb ENRICH data show BRII-179 priming drove 42% HBsAg loss in hepatitis B. Read the full results and what they mean for a functional cure.

Johnson & Johnson's Rybrevant Faspro earns FDA accelerated approval for recurrent or metastatic HNSCC. Learn who qualifies ...

Roche is using Chai Discovery's AI models across multiple drug discovery programs. Read the full story on this latest 2026 ...

Alamar Biosciences (Nasdaq: ALMR) and Finland-based Nightingale Health have launched UKB-PRISM, a study of 80,000 UK Biobank ...

Step Pharma shares early Phase II VECTRA trial data for dencatistat in essential thrombocythaemia (ET) ahead of ASH 2026.

Acepodia dosed the first patient in a Phase I trial of ACE723, a GPC3-targeted dual-payload ADC for liver cancer. Read the ...

Moderna's mRNA-2808 yields four confirmed responses in Phase I/II myeloma study targeting BCMA, GPRC5D and FcRH5. Read the ...

Mondego Bio has begun first-in-human dosing of MB-388, an oral PTPN2/PTPN1 inhibitor aimed at overcoming cancer immunotherapy ...

Cambridge spinout T-Therapeutics closes $133m Series B to advance TCR bispecifics in cancer and autoimmune disease. Read the full story for what's next.

Alethio Therapeutics raises USD 90M Series A to advance ATX-011, a G6B antibody for essential thrombocythaemia. Read the ...

Emvena Therapeutics launches with seed funding from the Penn-BioNTech PxB Fund to build placenta-targeted mRNA medicines.